m6A甲基化对肺癌向治疗耐药性的作用
Huange Xue1, Yufei Ma2, Kaiwen Guan1
1Department of Radiation Oncology, The First Affiliated Hospital of Xinxiang Medical University Xinxiang, Henan, China.
American journal of cancer research
|July 15, 2024
概括
N6-甲基氨酸 (m6A) RNA修饰在肺癌 (LC) 耐药性中发挥着关键作用. 了解m6A功能对于克服向治疗耐药性和预防LC患者的疾病复发至关重要.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 向治疗改善了肺癌 (LC) 的结果,但获得的耐药性和复发仍然是重大挑战.
- 表观遗传机制,特别是RNA修饰,越来越多地被认为是癌症获得药物耐药性的驱动因素.
- N6-甲基氨酸 (m6A) 是一种普遍存在的RNA修饰,影响RNA命运和癌症进展.
研究的目的:
- 综述和总结目前对N6-甲基氨酸 (m6A) RNA甲基化在肺癌 (LC) 向治疗耐药性的发展中的作用的理解.
主要方法:
- 文献综述和对肺癌中m6ARNA甲基化现有研究的综合.
- 对调查m6A对癌细胞行为和药物反应的功能影响的研究分析.
主要成果:
- N6-甲基氨酸 (m6A) 修改涉及调节肺癌细胞生长,入侵和对向疗法的抵抗.
- m6A调节关键的细胞过程,包括RNA稳定性,剪接,转录,翻译和降解,为治疗挑战做出贡献.
结论:
- N6-甲基氨酸 (m6A) 是肺癌 (LC) 进展和对向治疗获得的耐药性的关键表观遗传调节剂.
- 对m6A机制的进一步研究可能会揭示新的治疗策略,以克服耐药性并改善LC患者的治疗结果.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Epigenetic Regulation
31.0K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.0K
Phase II Reactions: Methylation Reactions
174
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
174
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K


